Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Semiconductors, Circuits & Optics
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
UNIVERSITEIT HASSELT currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are being handled by 2 distinct examiners, meaning each pending case is under the review of a different official. Joseph Paul Miano is identified as the busiest examiner.
Both 2 pending office actions are located within 1 distinct art unit. This concentration suggests that while the company is dealing with 2 distinct examiners, those examiners are likely working within the same specialized technical group at the patent office. The presence of the 1 distinct art unit allows for some comparison of how different examiners in the same group approach the company's biotechnology filings.
For practitioners, the fact that the busiest examiner pending count is 1 indicates a balanced workload across the examiners. Strategy for this portfolio involves managing separate dialogues within the same group. The outcomes will depend on the individual interpretations of the officials involved, as no individual examiner handles more than 1 pending action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MIANO, JOSEPH PAUL | 1 | 36.0% | +63.3% |
| IBRAHIM, MEDINA AHMED | 1 | 87.4% | +12.2% |
| TRAN, HOANG Q | 1 | 67.7% | +32.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18263997 | METHOD FOR DETERMINING A TOXICITY AND/OR GROWTH PROMOTION EFFECT OF A TREATMENT OR COMPOUND | IBRAHIM, MEDINA AHMED | 37d overdue |
| 18839788 | HUMAN TOOTH ORGANOIDS | MIANO, JOSEPH PAUL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18263997 | METHOD FOR DETERMINING A TOXICITY AND/OR GROWTH PROMOTION EFFECT OF A TREATMENT OR COMPOUND | IBRAHIM, MEDINA AHMED | 37d overdue |
| 18839788 | HUMAN TOOTH ORGANOIDS | MIANO, JOSEPH PAUL | — |
| 17998877 | Thermal Monitoring in Laminate Structures | TRAN, HOANG Q | — |
| Art Unit | Apps |
|---|---|
| 1662 | 1 |
| 2874 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18839788 | HUMAN TOOTH ORGANOIDS | MIANO, JOSEPH PAUL | — | §102§103§112 | Non-Final OA | — | Pending | Aug 20, 2024 |
| 18263997 | METHOD FOR DETERMINING A TOXICITY AND/OR GROWTH PROMOTION EFFECT OF A TREATMENT OR COMPOUND | IBRAHIM, MEDINA AHMED | 1662 | §103§112 | Non-Final OA | 37d overdue | Pending | Aug 02, 2023 |
| 17998877 | Thermal Monitoring in Laminate Structures | TRAN, HOANG Q | 2874 | §103 | Final Rejection | — | Pending | Nov 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial